Similar articles for PMID: 25952787

Year	Number of Results
1984	2
1996	1
2003	1
2010	3
2011	2
2012	16
2013	30
2014	39
2015	47
2016	45
2017	37
2018	49
2019	40
2020	46
2021	50
2022	40
2023	12
2024	1

1

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA. Calzavara Pinton P, et al. Future Oncol. 2015;11(9):1429-35. doi: 10.2217/fon.15.20. Future Oncol. 2015. PMID: 25952787 Review.

2

Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

Lyseng-Williamson KA, Keating GM. Lyseng-Williamson KA, et al. Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6. Am J Clin Dermatol. 2013. PMID: 23329081

3

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Dessinioti C, Plaka M, Stratigos AJ. Dessinioti C, et al. Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50. Future Oncol. 2014. PMID: 24941979 Clinical Trial.

4

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N. Erdem GU, et al. Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. Curr Med Res Opin. 2015. PMID: 25690490 Review.

5

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Chang AL, et al. J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1. J Am Acad Dermatol. 2014. PMID: 24189279 Free article. Clinical Trial.

6

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL. Proctor AE, et al. Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Ann Pharmacother. 2014. PMID: 24259609 Review.

7

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators. Sekulic A, et al. J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021. J Am Acad Dermatol. 2015. PMID: 25981002 Clinical Trial.

8

Vismodegib in the treatment of advanced BCC.

O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM. O'Kane GM, et al. Ir Med J. 2014 Jul-Aug;107(7):215-6. Ir Med J. 2014. PMID: 25226719

9

Vismodegib: A Review in Advanced Basal Cell Carcinoma.

Frampton JE, Basset-Séguin N. Frampton JE, et al. Drugs. 2018 Jul;78(11):1145-1156. doi: 10.1007/s40265-018-0948-9. Drugs. 2018. PMID: 30030732 Review.

10

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.

Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Peris K, et al. Future Oncol. 2015;11(4):703-12. doi: 10.2217/fon.14.281. Future Oncol. 2015. PMID: 25686123 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

394 results

Results by year